Cellectis (ALCLS) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on gene-editing technologies for allogeneic CAR T-cell therapies in immuno-oncology and gene therapy for genetic diseases.

• Develops off-the-shelf, gene-edited CAR T-cell products derived from healthy donors, aiming for global distribution and cost-effectiveness.

• Proprietary gene-editing enables enhanced safety, efficacy, and control features in product candidates.

Financial performance and metrics

• Cash and cash equivalents were $127.6 million as of March 31, 2025, down from $143.3 million at year-end 2024.

• Total financial liabilities stood at $108.8 million as of March 31, 2025.

• Shareholders' equity was $116.2 million as of March 31, 2025.

• Net loss for the first quarter of 2025 was $18.1 million, compared to a net loss of $36.8 million for the full year 2024.

Use of proceeds and capital allocation

• Net proceeds from any offering are intended for working capital and general corporate purposes, with significant discretion retained for allocation.